BiotechTube
Pathalys Pharma

Pathalys Pharma

Durham, United States· Est.
pathalys.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $240M

Overview

Pathalys Pharma is a late-stage biotech company targeting critical unmet needs in end-stage chronic kidney disease, with its lead program, upacicalcet, in Phase 3 development for secondary hyperparathyroidism (SHPT). The company is well-capitalized, having secured a $105 million Series B financing in August 2024 to fund its NDA submission and pre-commercialization efforts. With a strategic focus on the dialysis patient population and backing from key industry investors, Pathalys is positioned to advance a pipeline of potential therapeutics for this underserved patient group.

NephrologyChronic Kidney Disease

Technology Platform

Development of enhanced formulations and delivery methods for therapeutics in end-stage kidney disease, initially focused on novel calcimimetics for secondary hyperparathyroidism.

Funding History

2
Total raised:$240M
Venture$105M
Series A$135M

Opportunities

The large, concentrated hemodialysis patient population with SHPT represents a multi-billion dollar market with clear unmet needs around tolerability and convenience.
Pathalys's intravenous administration at the time of dialysis offers a potential adherence advantage and seamless integration into clinic workflow.
Success with upacicalcet could establish a commercial foothold in nephrology clinics for future pipeline products.

Risk Factors

The company faces significant clinical risk as its value depends entirely on the success of its ongoing Phase 3 trial for upacicalcet.
Even if approved, it must compete against established therapies in a cost-conscious dialysis market dominated by Medicare reimbursement.
As a single-asset company, it has high concentration risk with limited near-term diversification.

Competitive Landscape

Upacicalcet competes in the established calcimimetic market for SHPT, which includes oral cinacalcet (generic and branded) and intravenous etelcalcetide. The competitive differentiation hinges on demonstrating a superior tolerability profile, particularly reduced hypocalcemia and GI events, and the convenience of its specific intravenous delivery method. Other competitors include vitamin D analogs and phosphate binders used in combination therapy.

More companies in Small Molecule Drugs →More companies in United States →